Recent research has identified various biological markers associated with type 2 diabetes (T2D), including gut microbiome signatures, blood metabolites, and tissue-specific genetic drivers.
The studies, which employed different methodologies and populations, highlight the complex and multifactorial nature of the disease.
Gut Microbiome and Metabolite Findings
Two studies investigated the relationship between the gut microbiome and T2D, focusing on different aspects of the disease.
Gut Microbiota in T2D Patients with Coronary Artery Disease
A case-control study published in Scientific Reports examined differences in gut microbiota and plasma metabolites among three groups: healthy controls, type 2 diabetes mellitus (T2DM) patients, and T2DM patients with coronary atherosclerotic heart disease (T2DM-CAD). The study, which included 30 participants (10 per group) recruited from July to November 2022, used fecal metagenomic sequencing and plasma metabolomic profiling.
The analysis identified eight gut microorganisms and eight metabolites with potential diagnostic relevance for distinguishing T2DM-CAD. Bacteroides sp. CAG_875 and 12-ketolithocholic acid showed area under the curve (AUC) values of 0.90 and 0.80, respectively. A Random Forest Analysis identified candidate biomarkers, and Spearman correlation assessed microbe-metabolite interactions. The study noted that 17 clinical indicators correlated with 30 specific gut microbes.
The authors stated that the study's small sample size and correlation-based results require further validation in larger independent cohorts.
Gut Microbiome and Incident Type 2 Diabetes in a Swedish Cohort
A prospective cohort study published in Cell Reports Medicine examined associations between gut microbiome features and incident T2D in 4,685 Swedish adults (mean age 73.9 years), of whom 383 developed T2D during a median follow-up of 5.3 years.
- Microbial Diversity: α-diversity showed an inverse association with incident T2D that was not statistically significant. β-diversity associations with T2D risk were not consistent across sensitivity analyses.
- Microbial Species: Nine species were robustly associated with incident T2D.
- Positively associated: Alistipes communis, Alistipes finegoldii, Akkermansia muciniphila, Desulfovibrio piger, GGB3614 SGB4886 (Lachnospiraceae), and Ruminococcus gnavus.
- Negatively associated: Erysipelotrichaceae bacterium, Clostridia unclassified SGB6317, and Coprococcus catus.
- Functional Potential: Three gut metabolic modules (GMMs) showed consistent associations. The asparagine degradation GMM was associated with higher T2D risk; the non-oxidative pentose phosphate pathway and mannose degradation GMMs were associated with lower risk.
- Dietary Fiber Interaction: The positive association between A. muciniphila and T2D risk was strongest among individuals with low dietary fiber intake (≤20 g/day). Among incident T2D cases, higher A. muciniphila abundance was associated with higher odds of inflammation in the context of low fiber intake, but lower odds with high fiber intake.
The authors stated that the findings provide insights into T2D etiology but cautioned that residual confounding, the older Swedish cohort, single-time-point stool sampling, and observational design limit causal interpretation and generalizability.
Blood Metabolite Signature for Risk Prediction
A study published in Nature Medicine by researchers from Mass General Brigham and Albert Einstein College of Medicine identified circulating blood metabolites linked to future T2D risk and developed a multi-metabolite risk signature for risk prediction.
Researchers analyzed 469 circulating metabolites in blood samples from 23,634 individuals without diabetes, spanning diverse racial and ethnic backgrounds, over a follow-up period of up to 26 years. A total of 235 metabolites, including 67 newly identified in this study, showed an association with the risk of developing T2D. These associations remained statistically significant after accounting for conventional risk factors such as obesity, blood lipids, blood pressure, lifestyle factors (physical activity, diet quality), and kidney function.
Many identified metabolites demonstrated genetic links to signaling pathways and clinical traits relevant to T2D pathophysiology, including insulin resistance, glucose and insulin responses, ectopic fat deposition, energy and lipid regulation, and liver function.
Lifestyle factors, particularly physical activity, obesity, and diet, explained a greater proportion of variability in diabetes-associated metabolites compared to non-associated metabolites.
Specific metabolites were suggested to mediate the statistical link between these lifestyle factors and future T2D risk. For example, metabolites mediating the inverse association between physical activity and diabetes risk were primarily involved in ectopic fat deposition-related insulin resistance and liver function impairment.
The study developed a signature of 44 metabolites that improved T2D risk prediction when added to conventional clinical risk factors like age, sex, BMI, and blood glucose. This metabolomic signature was validated across multiple cohorts.
The authors noted that due to the observational study design, causality could not be definitively established, though genetic analyses strengthened causal inference for some metabolites. The study population was predominantly non-Hispanic White (77%).
Tissue-Specific Genetic Drivers
Two reports from the same study, published in Nature Metabolism, identified hundreds of genetic drivers for T2D in specific tissues, highlighting the tissue-specific nature of disease mechanisms and their commonality across various populations.
The research, led by scientists from the University of Massachusetts Amherst and Helmholtz Munich, analyzed genetic data from over 2.5 million individuals globally. The team utilized genome-wide association data from the Type 2 Diabetes Global Genomics Initiative, which includes genetic information from over 700,000 individuals of non-European ancestry.
Key findings include:
- Causal Evidence: Causal evidence was found for 676 genes across seven tissues relevant to diabetes (adipose tissue, liver, skeletal muscle, pancreatic cells, and others).
- Blood Sample Limitations: Blood samples captured only 18% of the genes with a causal effect identified in primary diabetes tissues, while 85% of genes detected in diabetes-relevant tissues were absent in blood samples.
- Genetic Diversity: Analyzing only blood tests identified 335 genes and 46 proteins with causal effects on T2D risk. Broadening the analysis to tissue-specific gene expression increased this number to 676 genes. Some genes exhibited consistent effects across ancestry groups, while others emerged specifically when data from historically underrepresented populations were included.
- Newly Identified Genes: Newly identified tissue-specific genes include BAK1 (involved in cell death), as well as CPXM1 and HIBCH.
The analysis specifically focused on genetic variants near genes affecting gene expression or protein abundance, testing over 20,000 genes and 1,630 proteins.
The authors noted that previous genome-wide association studies (GWAS) and causal analyses have predominantly relied on blood samples from individuals of European ancestry. Future steps involve validating these computational findings through real-world studies, expanding tissue and protein data beyond European ancestry, and increasing resolution via single-cell analyses.